LL-37: The Complete Guide

Overview

LL-37 is the only cathelicidin-derived antimicrobial peptide found in humans. It is a 37-amino-acid peptide cleaved from its precursor protein hCAP-18 (human cationic antimicrobial protein 18) by proteinase 3, an enzyme released from neutrophils during immune activation. Unlike many peptides used in regenerative medicine, LL-37 is endogenous — the human body naturally produces it as a first-line defense against microbial invasion (Zanetti, 2004).

LL-37 is expressed by neutrophils, macrophages, epithelial cells lining the skin, respiratory tract, gastrointestinal tract, and urogenital tract. It is also found in wound fluid, sweat, saliva, and breast milk. Its broad distribution reflects its role as a multifunctional component of innate immunity — the body's immediate, non-specific defense system that operates before adaptive immune responses are activated (Vandamme et al., 2012).

The peptide demonstrates broad-spectrum antimicrobial activity against Gram-positive bacteria, Gram-negative bacteria, fungi, and enveloped viruses. Beyond direct microbial killing, LL-37 modulates immune responses, promotes wound healing, stimulates angiogenesis, and disrupts bacterial biofilms — structured microbial communities that are resistant to conventional antibiotics (Bowdish et al., 2005).

Therapeutic interest in LL-37 has grown due to the global rise in antibiotic-resistant infections. As a naturally occurring antimicrobial that kills bacteria through membrane disruption — a mechanism that is difficult for microbes to develop resistance against — LL-37 represents a potential alternative or adjunct to conventional antibiotics. However, therapeutic applications remain primarily at the preclinical stage. No FDA-approved LL-37 therapeutic exists, and clinical trial data in humans is limited.

Synthetic LL-37 has been available through research chemical suppliers and select compounding pharmacies. It is used in research settings and, to a limited extent, in integrative medicine practices focused on immune support and wound healing.

Quick Facts

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

How It Works

Direct Antimicrobial Activity

LL-37's primary antimicrobial mechanism involves physical disruption of microbial cell membranes. The peptide carries a net positive charge (+6) and adopts an amphipathic alpha-helical structure — one side is hydrophobic (water-repelling), the other hydrophilic (water-attracting). This structure allows LL-37 to bind to the negatively charged phospholipid membranes of bacteria, fungi, and enveloped viruses (Turner et al., 1998).

Upon binding, LL-37 inserts into the lipid bilayer and forms pores or disrupts membrane integrity through several proposed models:

• Toroidal pore model: LL-37 molecules aggregate and bend the membrane inward, creating transmembrane pores that allow uncontrolled ion flux and cell death
• Carpet model: At higher concentrations, LL-37 coats the membrane surface like a carpet until a critical threshold causes membrane fragmentation
• Detergent-like solubilization: LL-37 micelles extract lipid components from the membrane, dissolving it in a detergent-like fashion

This physical mechanism of killing is significant because it is inherently difficult for bacteria to develop resistance against. Altering membrane composition to resist LL-37 would compromise basic cellular functions. This contrasts with conventional antibiotics, which target specific enzymes or processes that bacteria can modify through single-gene mutations (Bowdish et al., 2005).

Immune Modulation

Beyond direct killing, LL-37 acts as an immune modulator — coordinating the body's broader immune response:

• Chemotaxis: LL-37 recruits immune cells (neutrophils, monocytes, T cells, mast cells) to sites of infection through formyl peptide receptor-like 1 (FPRL1/FPR2) signaling (Yang et al., 2000)
• Cytokine regulation: LL-37 modulates the production of pro-inflammatory and anti-inflammatory cytokines, fine-tuning the immune response to avoid both insufficient and excessive inflammation (Vandamme et al., 2012)
• LPS neutralization: LL-37 binds and neutralizes lipopolysaccharide (LPS), a component of Gram-negative bacterial cell walls that triggers sepsis-associated inflammatory cascades. This anti-endotoxin activity is relevant to sepsis research (Scott et al., 2002)
• Dendritic cell activation: LL-37 enhances dendritic cell maturation and antigen presentation, bridging innate and adaptive immunity (Davidson et al., 2004)

Biofilm Disruption

Bacterial biofilms — structured communities encased in a protective extracellular matrix — are a major clinical challenge. Biofilm-associated bacteria are 100–1,000 times more resistant to antibiotics than their free-floating (planktonic) counterparts. LL-37 has been shown to inhibit biofilm formation and disrupt established biofilms at sub-antimicrobial concentrations — concentrations too low to kill planktonic bacteria but sufficient to interfere with biofilm architecture (Overhage et al., 2008).

This anti-biofilm activity occurs through multiple mechanisms: interference with quorum sensing (bacterial communication), reduction of bacterial surface motility, and direct degradation of the biofilm matrix. This property is particularly relevant to chronic wound infections, implant-associated infections, and cystic fibrosis lung infections, where biofilms are a primary driver of treatment resistance.

Wound Healing and Angiogenesis

LL-37 promotes wound healing through several pathways:

• Keratinocyte migration: LL-37 stimulates keratinocyte migration and proliferation, accelerating re-epithelialization of wounds (Heilborn et al., 2003)
• Angiogenesis: LL-37 promotes new blood vessel formation through FPRL1-mediated endothelial cell signaling, increasing blood supply to healing tissue (Koczulla et al., 2003)
• Fibroblast activation: LL-37 stimulates fibroblast proliferation and extracellular matrix deposition, supporting tissue remodeling

Notably, LL-37 expression is upregulated in wound fluid during normal healing but is deficient in chronic, non-healing wounds — an observation that has driven interest in topical LL-37 as a wound-healing therapeutic (Heilborn et al., 2003).

Vitamin D Connection

LL-37 expression is regulated by vitamin D. The CAMP gene (encoding the hCAP-18 precursor) contains a vitamin D response element (VDRE) in its promoter region. When 1,25-dihydroxyvitamin D₃ (calcitriol, the active form of vitamin D) binds to the vitamin D receptor, it directly upregulates transcription of hCAP-18/LL-37. This vitamin D–cathelicidin axis is one mechanism by which vitamin D supports immune function (Wang et al., 2004).

This relationship has clinical implications: vitamin D deficiency is associated with reduced LL-37 levels and increased susceptibility to infections, particularly tuberculosis. Vitamin D supplementation has been studied as a strategy to enhance endogenous LL-37 production (Liu et al., 2006).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Research

Antimicrobial Activity

LL-37 demonstrates broad-spectrum antimicrobial activity in laboratory and animal studies:

• Gram-positive bacteria: Effective against Staphylococcus aureus (including MRSA), Streptococcus species, and Enterococcus faecalis in vitro (Turner et al., 1998)
• Gram-negative bacteria: Active against Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii. Anti-pseudomonal activity is particularly notable given the organism's intrinsic antibiotic resistance (Overhage et al., 2008)
• Fungi: Demonstrated antifungal activity against Candida albicans and Candida krusei, disrupting fungal cell membranes through similar charge-based mechanisms (Den Hertog et al., 2005)
• Viruses: Antiviral activity documented against enveloped viruses including influenza A, HIV, herpes simplex virus (HSV), and respiratory syncytial virus (RSV). LL-37 disrupts viral envelopes and interferes with viral attachment to host cells (Barlow et al., 2011)
• Mycobacteria: Activity against Mycobacterium tuberculosis, with the vitamin D–LL-37 axis playing a role in macrophage-mediated mycobacterial killing (Liu et al., 2006)

Biofilm-Related Research

• Pseudomonas aeruginosa biofilms: LL-37 at sub-inhibitory concentrations (1/16 MIC) reduced biofilm formation by approximately 40–60% and disrupted pre-formed biofilms. The mechanism involved suppression of type IV pilus-driven twitching motility and interference with quorum sensing (Overhage et al., 2008)
• Staphylococcus epidermidis biofilms: LL-37 inhibited biofilm formation on plastic surfaces at concentrations below the minimum inhibitory concentration for planktonic bacteria (Vandamme et al., 2012)
• Catheter-associated biofilms: In vitro models of catheter biofilm infections showed that LL-37 coating reduced bacterial adherence and biofilm thickness — relevant to implant-associated infection prevention

Wound Healing

• Chronic venous leg ulcers (human): A Phase I/II clinical trial evaluated topical LL-37 (0.5 mg/mL and 1.6 mg/mL) applied to chronic venous leg ulcers in 34 patients. Treatment was well-tolerated, and the higher-dose group showed a trend toward accelerated healing compared to placebo. This represents the most advanced human clinical data for LL-37 to date (Grönberg et al., 2014)
• LL-37 deficiency in chronic wounds: Analysis of wound fluid from non-healing ulcers revealed reduced LL-37 levels compared to normally healing wounds, supporting a role for LL-37 supplementation in wound-healing impairment (Heilborn et al., 2003)
• Diabetic wound models: In diabetic mouse models, topical LL-37 accelerated wound closure, increased angiogenesis, and enhanced re-epithelialization compared to vehicle controls (Koczulla et al., 2003)

Anti-Cancer Research

• Melanoma: Intratumoral LL-37 injection reduced tumor growth in mouse melanoma models. The mechanism involved both direct cytotoxicity to tumor cells and enhanced anti-tumor immune responses (Kuroda et al., 2012)
• LL-37 gene therapy: A Phase I clinical trial evaluated intratumoral injection of LL-37-encoding plasmid DNA in patients with advanced melanoma. The approach was feasible and well-tolerated; immunological responses were observed in some patients (Mader et al., 2014)
• Dual role in cancer: LL-37's effects on cancer are complex and context-dependent. While anti-tumor effects have been documented in melanoma and some other models, LL-37 has also been associated with tumor-promoting effects in ovarian and breast cancer models — likely through its angiogenic and proliferative properties. This dual role complicates therapeutic development (Vandamme et al., 2012)

Sepsis and Endotoxemia

• LPS neutralization: LL-37 binds LPS with high affinity, preventing it from activating the TLR4 signaling cascade that drives septic shock. In murine endotoxemia models, LL-37 administration reduced circulating TNF-α and IL-6 levels and improved survival (Scott et al., 2002)
• Cecal ligation and puncture (CLP) model: In this standard sepsis model, LL-37 treatment reduced bacterial burden, attenuated organ damage, and improved survival rates in mice (Bowdish et al., 2005)

Respiratory Infections

• Cystic fibrosis: LL-37 levels are reduced in cystic fibrosis airway fluid due to inactivation by the high salt and mucus environment. Aerosolized LL-37 has been studied in vitro for its ability to kill CF-associated Pseudomonas and disrupt airway biofilms (Overhage et al., 2008)
• Tuberculosis: The vitamin D–LL-37 axis plays a documented role in macrophage-mediated killing of M. tuberculosis. Clinical trials of vitamin D supplementation to boost LL-37 levels in TB patients have shown mixed results (Liu et al., 2006)

Limitations of the Research

• Primarily preclinical: Most data comes from cell culture and animal models. Translation to human efficacy is uncertain.
• Stability concerns: LL-37 is susceptible to degradation by proteases in biological fluids, which may limit in vivo efficacy compared to in vitro results.
• Toxicity at high concentrations: At concentrations above therapeutic ranges, LL-37 can damage host cell membranes (hemolysis, cytotoxicity). The therapeutic window requires careful characterization.
• Cost of synthesis: LL-37 is a 37-amino-acid peptide, making chemical synthesis more expensive than shorter therapeutic peptides.
• Dual role in cancer: Context-dependent pro-tumor and anti-tumor effects complicate clinical development.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Uses

FDA Status

LL-37 has no FDA-approved indication. It is not classified as a drug, dietary supplement, or approved biologic. Any clinical use is considered experimental. Synthetic LL-37 is primarily available through research chemical suppliers.

Reported Clinical Applications

The following uses are reported in research literature and integrative medicine practice. They are based on preclinical evidence, limited clinical data, and provider experience — not FDA-approved indications.

What LL-37 Is NOT Used For

• Replacement for antibiotics: LL-37 is not a substitute for prescribed antibiotic therapy in acute bacterial infections requiring established treatment protocols.
• Cancer treatment: Despite preclinical anti-tumor data, LL-37's dual role in cancer (pro-tumor in some contexts) makes clinical use in oncology premature and potentially harmful without explicit oncologic guidance.
• Performance enhancement: LL-37 has no ergogenic or muscle-building properties.
• Autoimmune conditions: LL-37 is implicated in the pathogenesis of certain autoimmune conditions (psoriasis, lupus). Exogenous supplementation in these conditions could theoretically worsen disease activity.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Dosing

Commonly Reported Protocols

Dosing protocols above are derived from published clinical and preclinical research. Key references: Grönberg et al., 2014 (Wound Repair and Regeneration) · Vandamme et al., 2012 (Cellular Immunology) · Zanetti, 2004 (Journal of Leukocyte Biology)

Treatment Duration

No established evidence base exists for optimal treatment duration. Commonly reported patterns include:

• Acute infection support: 7–14 days of daily use during active infection, then discontinue
• Chronic wound healing: Application for the duration of wound healing (typically 4–12 weeks in the clinical trial setting)
• Immune support protocol: 4–6 weeks on, reassess based on clinical response
• Biofilm-targeted protocol: 4–8 weeks, often used as adjunct to antimicrobial therapy

Administration

Synthetic LL-37 for subcutaneous use is typically supplied as a lyophilized (freeze-dried) powder requiring reconstitution with bacteriostatic water. Preparation and administration should be demonstrated and supervised by a prescribing healthcare provider or pharmacist. Topical formulations require compounding under sterile conditions.

Storage

• Lyophilized powder: Store at -20°C for long-term storage or 2–8°C (refrigerated) for short-term use. LL-37 is more sensitive to degradation than shorter peptides due to its length.
• Reconstituted solution: Refrigerate (2–8°C) and use within 1–2 weeks. LL-37 is susceptible to protease degradation; avoid repeated freeze-thaw cycles.
• Topical preparations: Store per compounding pharmacy instructions, typically refrigerated.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Results: What Users Report

Reported Timeline

Clinical Trial Results

The Grönberg et al. Phase I/II trial provides the most robust human data:

• 34 patients with hard-to-heal venous leg ulcers were treated with topical LL-37 or placebo
• The higher-dose group (1.6 mg/mL) showed a trend toward faster wound healing compared to placebo
• Treatment was well-tolerated with no serious adverse events attributable to LL-37
• The trial was not powered to detect statistically significant differences in healing rates — it was designed primarily to assess safety and feasibility (Grönberg et al., 2014)

Contextualizing User Reports

Important considerations when evaluating reported results:

• Placebo effect: Particularly relevant for subjective endpoints like energy, well-being, and immune "support." Cannot be excluded without controlled trials.
• Concurrent treatments: Most users employ LL-37 alongside other therapies (antibiotics, wound care, supplements). Attributing improvement to LL-37 specifically is difficult.
• Selection bias: Users who experience positive results are more likely to report their experience than those who noticed no benefit.
• Variable product quality: Research chemical LL-37 varies in purity and potency. Different users may be receiving different effective doses.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Side Effects

Reported Side Effects

Note: These rates are based on limited clinical data and anecdotal reports — not from large Phase 3 trials. True incidence rates in humans have not been established.

Dose-Dependent Toxicity

Unlike many therapeutic peptides, LL-37 has a defined toxicity profile at higher concentrations. Because its mechanism of action involves membrane disruption, it can damage host cell membranes at concentrations above the therapeutic range:

• Hemolysis: LL-37 can lyse red blood cells at concentrations significantly above therapeutic doses (typically >50 µM in vitro). This sets an upper limit on systemic dosing (Turner et al., 1998).
• Cytotoxicity: At high concentrations, LL-37 can damage eukaryotic cell membranes, including epithelial cells and fibroblasts. The therapeutic window (concentration that kills microbes but spares host cells) exists because microbial membranes are more negatively charged than mammalian membranes, but it narrows at high doses.
• Mast cell degranulation: LL-37 can trigger mast cell degranulation and histamine release, potentially causing localized allergic-type reactions at higher concentrations (Vandamme et al., 2012).

Theoretical Risks and Concerns

• Autoimmune disease exacerbation: LL-37 has been identified as a key mediator in several autoimmune conditions. In psoriasis, LL-37-DNA complexes activate plasmacytoid dendritic cells through TLR9, driving the Type I interferon response that underlies disease pathogenesis (Lande et al., 2007). In systemic lupus erythematosus (SLE), LL-37 facilitates autoantibody production. Exogenous LL-37 supplementation in individuals with these conditions could theoretically worsen disease activity.
• Cancer considerations: LL-37 has demonstrated both anti-tumor and pro-tumor effects depending on the cancer type and context. Individuals with active malignancies should not use LL-37 without explicit oncologic guidance.
• Protease degradation: LL-37 is degraded by proteases present in blood and tissue fluids, which may limit systemic bioavailability and create unpredictable pharmacokinetics.
• Long-term safety: No long-term human safety data exists. All available data is from short-term studies (the longest clinical trial was 12 weeks for wound healing).

Drug Interactions

No formal drug interaction studies have been conducted. Theoretical interactions include:

• Immunosuppressants: LL-37 activates innate immune responses; concurrent use with immunosuppressive drugs could produce unpredictable effects on immune function.
• Anticoagulants: LL-37's membrane-active properties and potential effects on platelet function warrant monitoring in patients on anticoagulant therapy.
• Biologics for autoimmune disease: Given LL-37's role in autoimmune pathogenesis, concurrent use with biologics targeting similar pathways (TNF inhibitors, IL-17 inhibitors) may produce unpredictable interactions.

Contraindications

• Psoriasis or psoriatic arthritis — LL-37 is a documented driver of psoriatic inflammation
• Systemic lupus erythematosus (SLE) — LL-37 is implicated in SLE pathogenesis
• Active cancer — due to context-dependent pro-tumor effects
• Pregnancy and breastfeeding — no safety data available
• Children — no pediatric data available
• Known allergy to LL-37 or any component of the preparation

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Regulatory Status

FDA Status

LL-37 occupies a regulatory space characteristic of many research peptides:

• It has no Investigational New Drug (IND) application in the United States for any indication (though clinical trials have been conducted internationally)
• It is not listed on the FDA's bulk drug substance evaluation categories (Category 1, 2, or 3)
• It is not a controlled substance
• It is available through research chemical suppliers marketed "for research purposes only" or "not for human consumption"
• Select compounding pharmacies have prepared LL-37 formulations under provider prescriptions, operating under the general compounding framework rather than specific FDA guidance on LL-37

Clinical Trial Status

WADA Status

LL-37 falls under WADA's S0 category (Non-Approved Substances) — a blanket prohibition on pharmacological substances without regulatory approval for human therapeutic use. Athletes subject to WADA testing should consider LL-37 prohibited both in- and out-of-competition.

Research Chemical Market

LL-37 is available through peptide research chemical suppliers. Because it is a 37-amino-acid peptide, synthesis is more complex and expensive than shorter peptides, and purity can vary between suppliers. Key considerations:

• Products are not manufactured under pharmaceutical cGMP standards
• Purity varies; certificates of analysis (COAs) should be requested and verified
• LL-37 is more susceptible to degradation than shorter peptides due to its length and multiple protease-sensitive cleavage sites
• Storage and handling requirements are more stringent than for more stable peptides

International Status

LL-37 is not approved as a therapeutic agent in any major regulatory jurisdiction (FDA, EMA, MHRA, TGA). Clinical trials have been conducted in Sweden (wound healing) and Europe (gene therapy). Regulatory frameworks for peptide therapies vary by country, with some jurisdictions permitting provider-directed use of research-grade peptides under medical supervision.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Cost

Typical Pricing

Why LL-37 Costs More Than Shorter Peptides

LL-37 is a 37-amino-acid peptide — significantly longer than many therapeutic peptides (BPC-157 is 15 amino acids; most research peptides are 5–20 amino acids). Longer peptides are more expensive to synthesize because:

• Each amino acid coupling step has a yield less than 100%, and errors compound over longer sequences
• Purification is more complex (HPLC separation of the target peptide from truncated sequences)
• Quality verification requires more sophisticated analysis (mass spectrometry confirmation)
• Overall synthesis yield decreases exponentially with peptide length

Insurance Coverage

LL-37 is not covered by any insurance plan. It has no FDA-approved indication and cannot be billed under any drug benefit or prescription plan. All costs are out-of-pocket.

Cost Comparison: LL-37 vs. Related Treatments

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Questions & Answers

Myth: LL-37 is a natural antibiotic that replaces prescription antibiotics.

Answer: LL-37 is an endogenous antimicrobial peptide with broad-spectrum activity in laboratory settings. However, it is not a validated replacement for prescription antibiotics. Conventional antibiotics have decades of clinical trial data, established dosing, known pharmacokinetics, and regulatory approval. LL-37 has limited clinical data, no established human dosing for infection treatment, and unknown pharmacokinetics for systemic antimicrobial use. While LL-37 resistance is theoretically more difficult for bacteria to develop than conventional antibiotic resistance, this has not been validated in clinical practice (Bowdish et al., 2005).

Myth: Bacteria cannot develop resistance to LL-37.

Answer: While membrane disruption is more difficult to resist than enzyme-targeted antibiotic mechanisms, bacterial resistance to LL-37 does occur. Several bacterial species have evolved mechanisms to resist cathelicidins, including modification of cell surface charge (reducing LL-37 binding), production of proteases that degrade LL-37, and efflux pump upregulation. Staphylococcus aureus, for example, produces staphylokinase, which inactivates LL-37 (Vandamme et al., 2012). The barrier to resistance is higher than for conventional antibiotics, but it is not absolute.

Myth: Taking vitamin D is just as good as using LL-37.

Answer: Vitamin D supplementation does upregulate endogenous LL-37 production through the CAMP gene vitamin D response element (Wang et al., 2004). However, the magnitude of LL-37 increase from vitamin D supplementation is modest compared to exogenous LL-37 administration. Vitamin D supplementation is a strategy to support baseline innate immune function — it does not produce the pharmacological concentrations of LL-37 achieved through direct peptide administration. The two approaches serve different purposes and are not interchangeable.

Myth: LL-37 boosts the immune system without any risks.

Answer: LL-37 modulates immune function, but immune modulation is not inherently risk-free. LL-37 is a documented mediator in autoimmune pathogenesis: it drives the Type I interferon response in psoriasis (Lande et al., 2007), contributes to autoantibody production in SLE, and can trigger mast cell degranulation and histamine release. Individuals with autoimmune conditions, allergic disorders, or inflammatory diseases may experience adverse effects from exogenous LL-37 supplementation. "Immune support" is not a one-directional concept — enhanced immune activation can be harmful in the wrong context.

Myth: LL-37 cures cancer.

Answer: LL-37 has demonstrated anti-tumor effects in specific preclinical models (melanoma, some solid tumors), and a Phase I gene therapy trial has been conducted (Mader et al., 2014). However, LL-37 has also been associated with tumor-promoting effects in ovarian cancer and breast cancer models, likely through its angiogenic and cell-proliferative properties (Vandamme et al., 2012). The relationship between LL-37 and cancer is complex, context-dependent, and far from being clinically actionable. Exogenous LL-37 should not be used as a cancer therapy.

Myth: All antimicrobial peptides work the same way.

Answer: While antimicrobial peptides share general features (cationic charge, membrane activity), they differ significantly in spectrum, potency, host toxicity, immunomodulatory effects, and stability. LL-37 is unique among human antimicrobial peptides as the only cathelicidin, and its immunomodulatory properties (chemotaxis, cytokine regulation, LPS neutralization) are distinct from defensins and other antimicrobial peptide families. Therapeutic effects observed with LL-37 cannot be assumed for other antimicrobial peptides and vice versa (Zanetti, 2004).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Key Takeaways

Based on the available evidence:

• LL-37 is the only human cathelicidin antimicrobial peptide — a 37-amino-acid endogenous peptide produced by neutrophils, macrophages, and epithelial cells as a component of innate immune defense. It is naturally present in wound fluid, skin, respiratory tract, and mucosal surfaces.
• It demonstrates broad-spectrum antimicrobial activity against Gram-positive and Gram-negative bacteria (including MRSA and Pseudomonas), fungi, and enveloped viruses. Its membrane-disruption mechanism is inherently more resistant to bacterial adaptation than conventional antibiotic targets, though resistance is not impossible.
• Beyond direct antimicrobial activity, LL-37 modulates immune responses (recruiting immune cells, regulating cytokines, neutralizing LPS), disrupts bacterial biofilms, promotes wound healing, and stimulates angiogenesis.
• The evidence base is primarily preclinical. One Phase I/II human trial for chronic wound healing and one Phase I cancer gene therapy trial have been completed. No Phase 3 trials exist. Clinical use is based on preclinical data and limited clinical experience.
• It is not FDA-approved for any indication. LL-37 is available primarily through research chemical suppliers. It is not a controlled substance but is not approved for human therapeutic use.
• The safety profile includes specific risks that distinguish it from simpler peptides: dose-dependent host cell toxicity (hemolysis at high concentrations), documented roles in autoimmune disease pathogenesis (psoriasis, SLE), and context-dependent effects on cancer. These risks require careful clinical consideration.
• LL-37 expression is regulated by vitamin D, providing a mechanistic link between vitamin D status and innate immune function.
• Cost ranges from $150–$400/month depending on source and protocol, and is not covered by insurance. The longer peptide sequence makes synthesis more expensive than shorter therapeutic peptides.

Who Might Consider LL-37

Based on the available evidence, LL-37 may be worth discussing with a healthcare provider for individuals who:

• Have chronic, non-healing wounds that have not responded to conventional wound care
• Experience recurrent infections, particularly those involving antibiotic-resistant organisms or suspected biofilm involvement
• Are being managed by a provider experienced in antimicrobial peptide therapeutics
• Do not have autoimmune conditions (particularly psoriasis or SLE) that could be exacerbated
• Understand that the evidence is primarily preclinical and accept the associated uncertainty

Questions to Ask a Provider

• Is LL-37 appropriate for my specific condition, given the current evidence base?
• What route of administration (subcutaneous vs. topical) is most appropriate?
• Do I have any autoimmune conditions that could be worsened by LL-37?
• Where will the LL-37 be sourced, and what purity verification has been performed?
• What is the expected treatment duration, and how will we assess response?
• Are there interactions with my current medications?
• Should I optimize my vitamin D status as a complementary strategy?
• Are there conventional treatments I should try first or use alongside LL-37?

Sources & Further Reading

Comprehensive Reviews

• Zanetti (2004) — "Cathelicidins, multifunctional peptides of the innate immunity" — Journal of Leukocyte Biology
• Vandamme et al. (2012) — "A comprehensive summary of LL-37, the factotum human cathelicidin peptide" — Cellular Immunology
• Bowdish et al. (2005) — "Immunomodulatory activities of small host defense peptides" — Antimicrobial Agents and Chemotherapy

Antimicrobial Activity

• Turner et al. (1998) — "Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils" — Antimicrobial Agents and Chemotherapy
• Den Hertog et al. (2005) — "Candidacidal effects of cathelicidins" — Biological Chemistry
• Barlow et al. (2011) — "Antiviral activity of cathelicidin against influenza virus" — Infection and Immunity

Biofilm Research

• Overhage et al. (2008) — "Human host defense peptide LL-37 prevents bacterial biofilm formation" — Infection and Immunity

Immune Modulation

• Yang et al. (2000) — "LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1)" — Journal of Experimental Medicine
• Scott et al. (2002) — "An anti-infective peptide that selectively modulates the innate immune response" — Nature Biotechnology
• Davidson et al. (2004) — "The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization" — Journal of Immunology

Wound Healing

• Grönberg et al. (2014) — "Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers" — Wound Repair and Regeneration
• Heilborn et al. (2003) — "The cathelicidin antimicrobial peptide LL-37 is involved in re-epithelialization of human skin wounds" — Journal of Investigative Dermatology
• Koczulla et al. (2003) — "An angiogenic role for the human peptide antibiotic LL-37/hCAP-18" — Journal of Clinical Investigation

Vitamin D Connection

• Wang et al. (2004) — "Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression" — Journal of Immunology
• Liu et al. (2006) — "Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response" — Science

Anti-Cancer Research

• Kuroda et al. (2012) — "Antimicrobial peptide FF/CAP18 induces apoptotic cell death in tumor cells" — International Journal of Oncology
• Mader et al. (2014) — "Bovine lactoferricin and human cathelicidin LL-37 in cancer immunotherapy" — BioMetals

Autoimmune Disease Connection

• Lande et al. (2007) — "Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide" — Nature

Regulatory

• WADA: Prohibited List (current year)

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.